Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.37 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | TDO2 | P48775 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16341078 | 1.00 | IDO1 (0.45) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL1876903 | 1.00 | IDO1 (0.45) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL557913 | 0.97 | IDO1 (0.42) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL1728961 | 0.97 | IDO1 (0.42) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL1004099 | 0.97 | IDO1 (0.42) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL29109434 | 0.86 | IDO1 (0.36) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL30496913 | 0.86 | IDO1 (0.36) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL29109435 | 0.86 | IDO1 (0.36) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL31226763 | 0.84 | IDO1 (0.39) | IDO1TDO2ADRB2GBA1 | |
| SCHEMBL25078128 | 0.83 | IDO1 (0.33) | IDO1TDO2ADRB2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| CN-109384729-B | Pyrimidinedione compounds for cardiac disorders | 迈奥卡迪亚公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110734437-B | Pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof | 南京烁慧医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| EP-2299813-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269989-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| CN-101611020-A | 4-hydroxy-2-oxo-2, 3-dihydro-1, 3-benzothiazol-7-yl compounds for modulating beta 2 adrenoreceptor activity | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009152010-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-6329405-B1 | AS ILEAL BILE ACID TRANSPORTER INHIBITOR, FOR THERAPY OF HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ADRB2 397/4885OPRM1 4384/4885OPRD1 4380/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ADRB2 397/4885OPRM1 4384/4885OPRD1 4380/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ADRB2 397/4885OPRM1 4384/4885OPRD1 4380/4885 |
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | ADRB2 3/4885OPRM1 48/4885OPRD1 19/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | ADRB2 1854/4885OPRM1 1414/4885OPRD1 745/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | ADRB2 638/4885OPRM1 4583/4885OPRD1 4609/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | ADRB2 892/4885OPRM1 1651/4885OPRD1 1821/4885 |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ADRB2 397/4885OPRM1 4384/4885OPRD1 4380/4885 |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | ADRB2 892/4885OPRM1 1651/4885OPRD1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.